Tokyo Tape
Sign in
← Carna Biosciences

Half-year report · Q2

4572.TEDINET S100WEUS
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥251m2025-01-01 → 2025-06-30Cons.Net sales
Revenue¥636m2024-01-01 → 2024-12-31Cons.Net sales (5-year summary)
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Operating income−¥1.1bn2025-01-01 → 2025-06-30Cons.Operating income
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Ordinary income−¥1.1bn2025-01-01 → 2025-06-30Cons.Ordinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2025-01-01 → 2025-06-30Cons.Income before income taxes
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2025-01-01 → 2025-06-30Cons.Profit loss
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Total assets¥1.6bnat 2025-06-30Cons.Assets
Total assets¥2.8bnat 2024-12-31Cons.Assets
Total assets¥3.7bnat 2024-06-30Cons.Total assets (5-year summary)
Total liabilities¥244mat 2025-06-30Cons.Liabilities
Total liabilities¥297mat 2024-12-31Cons.Liabilities
Net assets / equity¥1.4bnat 2025-06-30Cons.Net assets
Net assets / equity¥2.5bnat 2024-12-31Cons.Net assets
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.1bnat 2025-06-30Cons.Cash and deposits
Cash and deposits¥2.1bnat 2024-12-31Cons.Cash and deposits
Cash & equivalents¥1.1bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31vCons.Cash and cash equivalents
Operating cash flow−¥995m2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥16m2025-01-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14m2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥567m2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-55.292025-01-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-121.642024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio85.1%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥251m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥251m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥51m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Liabilities and net assetsPrior1YearInstant2772115000JPY
Liabilities and net assetsCurrentQuarterInstant1635585000JPY
Net salesPrior1YTDDuration315642000JPY
Net salesCurrentYTDDuration251097000JPY
Cost of salesPrior1YTDDuration82630000JPY
Cost of salesCurrentYTDDuration77358000JPY
Gross profitPrior1YTDDuration233012000JPY
Gross profitCurrentYTDDuration173738000JPY
Selling general and administrative expensesPrior1YTDDuration1328013000JPY
Selling general and administrative expensesCurrentYTDDuration1226580000JPY
Operating incomePrior1YTDDuration-1095000000JPY
Operating incomeCurrentYTDDuration-1052841000JPY
Interest income noiPrior1YTDDuration2543000JPY
Interest income noiCurrentYTDDuration2999000JPY
Dividends income noiPrior1YTDDuration219000JPY
Dividends income noiCurrentYTDDuration1528000JPY
Foreign exchange gains noiPrior1YTDDuration27718000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration2395000JPY
Other noiCurrentYTDDuration98000JPY
Non operating incomePrior1YTDDuration32877000JPY
Non operating incomeCurrentYTDDuration4626000JPY
Interest expenses noePrior1YTDDuration1726000JPY
Interest expenses noeCurrentYTDDuration895000JPY
Guarantee commission noePrior1YTDDuration198000JPY
Guarantee commission noeCurrentYTDDuration198000JPY
Stock issuance cost noePrior1YTDDuration23109000JPY
Stock issuance cost noeCurrentYTDDuration91000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration5624000JPY
Non operating expensesPrior1YTDDuration25033000JPY
Non operating expensesCurrentYTDDuration6809000JPY
Ordinary incomePrior1YTDDuration-1087156000JPY
Ordinary incomeCurrentYTDDuration-1055024000JPY
Impairment loss elPrior1YTDDuration4228000JPY
Impairment loss elCurrentYTDDuration315000JPY
Extraordinary lossPrior1YTDDuration4228000JPY
Extraordinary lossCurrentYTDDuration315000JPY
Income before income taxesPrior1YTDDuration-1091384000JPY
Income before income taxesCurrentYTDDuration-1055340000JPY
Income taxes currentPrior1YTDDuration2785000JPY
Income taxes currentCurrentYTDDuration1985000JPY
Income taxes deferredPrior1YTDDuration-52000JPY
Income taxes deferredCurrentYTDDuration-1270000JPY
Income taxesPrior1YTDDuration2733000JPY
Income taxesCurrentYTDDuration714000JPY
Profit lossPrior1YTDDuration-1094118000JPY
Profit lossCurrentYTDDuration-1056054000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-1094118000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-1056054000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass